BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Dementia Researcher - ECPv6.14.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Dementia Researcher
X-ORIGINAL-URL:https://www.dementiaresearcher.nihr.ac.uk
X-WR-CALDESC:Events for Dementia Researcher
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20261025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20261112T150000
DTEND;TZID=Europe/London:20261112T160000
DTSTAMP:20261107T220316
CREATED:20261106T125632Z
LAST-MODIFIED:20261106T125632Z
UID:10002514-1794495600-1794499200@www.dementiaresearcher.nihr.ac.uk
SUMMARY:Beyond Single Biomarkers: Expanding AD Testing
DESCRIPTION:A 60-minute live webinar on Thursday 12 November 2026 at 3pm (UK time) on multi-analyte blood biomarker testing in Alzheimer’s disease clinical research\, with experts from Taudia and Quantigen. \nBlood-based biomarkers are playing a growing part in Alzheimer’s clinical trials\, and choosing the right markers and testing strategy matters. Much of the attention so far has gone on single markers such as pTau217. This session looks at a validated 5-plex laboratory-developed test (LDT) that measures pTau-217\, Aβ40\, Aβ42\, NfL and GFAP at the same time\, and at how markers of neuronal injury and astrocytic activation can add to amyloid and tau to give a broader view of the disease. \nSpeakers from Taudia and Quantigen will cover the validation\, analytical performance and clinical utility of the assay. Participants will: \n\nLearn about Taudia’s SPLASH technology for ultrasensitive detection.\nGain a clear understanding of how Quantigen validated Taudia’s AD 5-plex assay.\nLearn the key differences between an LDT and an IVD assay.\nCompare a 5-plex biomarker test with single-biomarker testing for AD\, including the clinical rationale for each target.\nExplore when an LDT assay is the right choice for clinical research.\n\nThe webinar is designed for clinical researchers and trial sponsors\, and combines expert presentations with moderated discussion and live audience Q&A. For the wider picture on where blood tests are heading in the UK\, see UK experts’ guidance on who should get an Alzheimer’s blood test. \nThis educational webinar is supported by Taudia. \nBooking\nThe webinar runs online via Zoom. Register through the Zoom registration page to get joining details. \n\nClick Here
URL:https://www.dementiaresearcher.nihr.ac.uk/event/beyond-single-biomarkers-expanding-ad-testing/
LOCATION:Online
CATEGORIES:Online,Seminar
ATTACH;FMTTYPE=image/jpeg:https://www.dementiaresearcher.nihr.ac.uk/wp-content/uploads/2026/11/ADPD-Education.jpg
END:VEVENT
END:VCALENDAR